INNOCORE TECHNOLOGIES BV

Their core work

INNOCORE Technologies is a Dutch biotech SME based in Groningen that specializes in controlled-release drug delivery technology for implantable medical devices. Their core capability appears to be the development of implant materials and systems that enable sustained, precise release of therapeutics within the body — applied in the DRIVE project to diabetes-reversing implants and in OcuTher to ocular drug delivery systems. As a private company with manufacturing-sector classification, they bridge material science and pharmaceutical engineering, translating drug delivery concepts into manufacturable implant products. Their value in consortia is as a specialist technology provider with hands-on production capability, not a pure research actor.

What they specialise in

How they've shifted over time

Both H2020 projects started within a single year of each other (2015–2016), and no keyword data is available, so a meaningful temporal evolution cannot be reliably established from this dataset alone. What can be said is that INNOCORE entered EU-funded research simultaneously across two application domains — diabetes implants and ocular therapeutics — suggesting a platform drug delivery technology with multi-indication potential rather than a single-disease focus. Whether they have since deepened one of these tracks or broadened further is not visible in the available H2020 data.

INNOCORE appears to be positioning a core controlled-release implant technology across multiple clinical areas; future collaborations are most likely in chronic-disease implants, ophthalmic devices, or other long-duration drug delivery applications.

How they like to work

INNOCORE has never served as a project coordinator in H2020, always entering consortia as a participant or third-party partner — consistent with a specialist supplier role rather than a project leadership role. Their 30 unique partners across 11 countries from only 2 projects is notably broad, indicating they have been embedded in large, multi-partner consortia. This profile suggests they are easiest to engage as a technology or manufacturing contributor in a consortium led by a research university or hospital, rather than as an independent project driver.

INNOCORE has accumulated 30 unique consortium partners across 11 countries from just two projects, implying they participated in large international consortia with diverse academic and industrial members. Their Groningen base places them in a strong Dutch life-sciences cluster, though their collaborative footprint is broadly European.

What sets them apart

INNOCORE is rare in combining private-company manufacturing capability with involvement in both a medtech RIA project and an MSCA training network — suggesting they operate at the interface of production readiness and early-stage research training. For consortium builders, this makes them a useful bridge between academic drug delivery research and manufacturable product concepts. As a Dutch SME in Groningen, they are also close to a dense cluster of pharmaceutical and biotech actors, which can add network value beyond their direct technical contribution.

Highlights from their portfolio

• DRIVE
  The largest funded project in their portfolio (EUR 600,812 EC contribution), targeting diabetes-reversing implants — a high-impact clinical application that directly reflects INNOCORE's implant drug delivery core technology.
• OcuTher
  An MSCA-ITN European Training Network in ocular drug delivery, demonstrating that INNOCORE's expertise is recognized at the level of training the next generation of researchers in this field, not just participating in applied projects.